For decades, artificial intelligence advanced in careful, mostly linear steps. Researchers built models. Engineers improved performance. Organizations deployed systems to automate specific tasks. Each ...

Anthropic launched Cowork, bringing the autonomous capabilities of its developer-focused Claude Code tool to non-technical ...

Surface Design Show 2026 commits to emerging design talent, with material innovation, sustainability and future-focused thinking at heart ...

Recursion Pharmaceuticals (RXRX) ended the recent trading session at $4.65, demonstrating a -4.12% change from the preceding day's closing price. This move lagged the S&P 500's daily gain of 0.26%.

Information pervades the universe, yet means nothing. Meaning emerged when matter organized into systems that could ...

The evidence shows that, under controlled conditions, LLM judges can align closely with clinician judgments on concrete, ...

Welcome to the era of "Action Drift," where your agents are negotiating trades your CRO won’t understand for another six ...

And its investments in AI could, eventually, lead to important monetization opportunities even beyond advertising, perhaps ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

While standard models suffer from context rot as data grows, MIT’s new Recursive Language Model (RLM) framework treats ...

Wondering if Recursion Pharmaceuticals at around US$4.67 a share is priced for its potential or still misunderstood by the market? This article walks through what the current numbers may be telling ...

Accelerating investment in artificial intelligence (AI) infrastructure serves as a strong secular tailwind for Micron. 10 ...